Charles River Laboratories stock traded near its yearly high on September 28, 2026, following a significant wave of analyst upgrades despite a weak reported revenue trend. Major financial institutions including Mizuho, JPMorgan, TD Cowen, and Robert W. Baird raised their price targets for the company, with Baird setting a target of USD 334.00 that implies over 13% upside from the current trading price.
Q2 2026 financial results showed GAAP revenue falling 2.7% to USD 1.00 billion and a net loss of USD 1.5 million driven by divestiture charges. However, on an adjusted non-GAAP basis, EPS reached USD 3.02, which beat the consensus estimate of USD 2.74. Organic revenue remained flat at 0.1% growth, while DSA revenue declined slightly but maintained organic momentum.
At its September 24 Investor Day, Charles River reaffirmed its 2026 organic revenue guidance and raised non-GAAP EPS expectations to a range of USD 11.15-11.45. The company also outlined long-term strategic goals, targeting 5% to 7% organic revenue growth for the 2027-2030 period and expecting cumulative savings exceeding USD 300 million through that timeframe.
The market reaction was positive as investors appear to value the raised analyst targets and improved adjusted earnings over the short-term GAAP miss. With a market capitalization of USD 14.2 billion, the stock sits within its 52-week range but close to the top end, suggesting confidence in the company's ability to execute on its cost-saving initiatives and future growth plans.
📈 Stock trades near 52-week high of USD 303.31.
🚀 JPMorgan upgraded to Overweight with USD 310 target.
💰 TD Cowen raised target to USD 325.
📊 Non-GAAP EPS beat estimates at USD 3.02.
🎯 Reaffirmed 2026 organic revenue growth guidance of 0-1%.
📈 Charles River Laboratories stock traded at USD 294.59, just 2.88% below its 52-week high of USD 303.31.
🚀 Mizuho raised its price target from USD 264.00 to USD 295.00 while maintaining a Neutral rating.
🔼 JPMorgan upgraded its stance from Neutral to Overweight with a new price target of USD 310.00.
💰 TD Cowen increased its target to USD 325.00, signaling strong institutional interest in the stock.
📊 Robert W. Baird raised its target to USD 334.00 with an Outperform rating, implying 13.37% upside.
💸 Q2 GAAP revenue declined 2.7% year-over-year to USD 1.00 billion due to divestiture impacts.
📉 GAAP net loss widened to USD 1.5 million, or USD 0.03 per share, compared to prior periods.
✅ Non-GAAP EPS beat estimates at USD 3.02 versus the consensus of USD 2.74.
🎯 Company reaffirmed 2026 organic revenue growth guidance between 0% and 1%.
📈 Charles River raised non-GAAP EPS guidance for 2026 to a range of USD 11.15-11.45.
🌱 Long-term target set for 5% to 7% organic revenue growth through the 2027-2030 period.
💡 Company expects to generate over USD 300 million in cumulative savings from 2027 through 2030.
📉 DSA revenue fell 1.9% to USD 606.5 million, though organic DSA revenue rose 0.2%.
Charles River Laboratories International (CRL) stock has surged 102.3% over the past year, trading around $294.44. This significant price appreciation raises questions regarding whether current valuations are fully supported by the company's underlying cash generation capabilities.
Analysts project that CRL's annual Free Cash Flow will grow into the early 2030s, driven by rising outsourced research demand in areas like pharmacokinetics, toxicology testing, and cell banking. The market appears to price these expectations into the current share price, particularly regarding the launch of rapid cell banking programs designed to shorten biopharma development timelines.
Simply Wall St analysis presents a split view on CRL's future trajectory. A bullish narrative suggests the company is 6% undervalued due to strategic moves securing access to non-human primate (NHP) supply, which is critical for modern drug development. Conversely, a bearish perspective argues the stock is roughly fairly valued but faces headwinds including dependence on animal testing, pricing pressure, demand softness, and execution risks from restructuring.
The article concludes that while CRL's growth and margin expansion could push the price higher, significant risks threaten long-term stability. Investors are advised to monitor how revenue expansion and profitability shifts align with the company's strategic outsourcing initiatives and operational restructuring efforts.
📈 Stock returned 102.3% over past 12 months trading near $294.44.
🧬 Launching rapid cell banking to shorten biopharma timelines and boost cash.
💰 Twelve-month Free Cash Flow reached $356.2 million with growth projected.
🦍 Securing non-human primate supply is critical for modern drug development.
⚠️ Risks include animal testing dependence, pricing pressure, and restructuring execution.
📈 Charles River Laboratories International stock has returned 102.3% over the past 12 months, trading at approximately $294.44.
🧬 The company is launching rapid cell banking programs aimed at shortening biopharma development timelines and converting outsourced demand into higher cash generation.
💰 Latest twelve-month Free Cash Flow sits at about $356.2 million, with analyst projections pointing to growth heading toward the early 2030s.
🦍 Strategic deals to expand and secure access to non-human primate (NHP) supply are highlighted as critical for modern drug development.
⚖️ Simply Wall St analysis presents a split view, with one narrative suggesting CRL is 6% undervalued while another deems it roughly fairly valued.
⚠️ Key risks threatening revenue growth and long-term stability include dependence on animal testing, pricing pressure, demand softness, and execution risks from restructuring.
Bullish Signals
Launching rapid cell banking programs to shorten biopharma timelines.
Analysts project significant annual Free Cash Flow growth by early 2030s.
Expanding NHP supply access supports bullish narrative of 6% undervaluation.
Biopharma pricing pressure and demand softness create headwinds.
Restructuring execution risks threaten margins and stability.
Bullish Signals
The company is launching rapid cell banking programs aimed at shortening biopharma development timelines and converting outsourced demand into higher cash generation.
Analysts project that CRL's annual Free Cash Flow will grow significantly, heading toward the early 2030s as outsourced research demand rises.
Recent strategic moves to expand access to non-human primate (NHP) supply are viewed as critical for modern drug development, supporting a bullish narrative of 6% undervaluation.
Risk Factors
Dependence on animal testing is cited as a risk that could threaten revenue growth and long-term stability.
The company faces potential headwinds from pricing pressure and demand softness in the biopharma sector.
Execution risks associated with ongoing restructuring efforts pose a threat to margins and operational stability.
Charles River Laboratories International reported second-quarter 2026 results that saw its stock fall 2.73% to close at $277.33 on the NYSE. While Q2 revenue declined 2.7% year-over-year to $1 billion, organic revenue growth was a modest 0.1%. Non-GAAP earnings per share dropped 3.2% to $3.02, though this figure still beat analyst consensus by 11.0%. The GAAP result showed a loss of $0.03 per share, primarily driven by a $63.7 million charge related to divestitures.
Operating performance varied significantly across business segments during the quarter. The Discovery and Safety Assessment (DSA) segment generated $606.5 million in revenue, down 1.9% year-over-year, yet achieved a GAAP operating margin of 20.5%. Conversely, the Manufacturing segment saw revenue decline by 6.3% to $188.1 million but expanded its non-GAAP operating margin to 37.8%, highlighting divergent profitability trends within the company's portfolio.
Despite the near-term stock decline and top-line contraction, management raised its full-year 2026 non-GAAP earnings outlook following strong booking activity. At the Global Healthcare Conference, the DSA segment reported a net book-to-bill ratio of 1.19 and sequential booking growth of 13%. This indicates that bookings are exceeding revenue, which should help rebuild backlog levels over time, although management characterized the recovery as gradual rather than an immediate acceleration.
The market is currently weighing conflicting signals regarding Charles River Laboratories' trajectory. The stock remains 8.56% below its 52-week high of $303.31, reflecting investor caution on the revenue decline and GAAP loss. However, the raised EPS guidance and robust booking metrics suggest a potential recovery case that hinges on successfully converting current bookings into future revenue streams in the coming quarters.
📉 CRL stock fell 2.73% after Q2 revenue dropped 2.7% to $1 billion.
💰 Non-GAAP EPS beat estimates at $3.02 despite a GAAP loss of $0.03/share.
🔬 Discovery segment posted $606.5M revenue with a 20.5% GAAP operating margin.
🚀 Management raised full-year 2026 non-GAAP EPS guidance to $11.15-$11.45.
📉 Revenue guidance revised to a 3.5%-2.5% decline due to near-term headwinds.
📉 Charles River Laboratories stock fell 2.73% to $277.33 following Q2 results where revenue dropped 2.7% year-over-year to $1 billion.
💰 Non-GAAP EPS decreased 3.2% to $3.02, though the result exceeded analyst consensus estimates by 11.0%.
📉 GAAP earnings showed a loss of $0.03 per share due to a $63.7 million charge primarily tied to divestitures.
🔬 The Discovery and Safety Assessment segment generated $606.5 million in revenue with a 20.5% GAAP operating margin.
🏭 Manufacturing revenue declined 6.3% to $188.1 million but saw its non-GAAP operating margin expand to 37.8%.
📈 The DSA segment reported a net book-to-bill ratio of 1.19 and sequential booking growth of 13%.
🚀 Management raised the full-year 2026 non-GAAP EPS guidance range to $11.15-$11.45 from the prior $10.80-$11.30.
📉 Revenue guidance was revised to a decline of 3.5% to 2.5%, reflecting near-term top-line headwinds.
📊 The company's market capitalization stood at approximately $13.36 billion as of September 23, 2026.
Bullish Signals
Raised FY26 EPS guidance to $11.15-$11.45.
Discovery segment net book-to-bill ratio hit 1.19.
Non-GAAP EPS of $3.02 beat estimates by 11%.
Manufacturing margin expanded to 37.8%.
Risk Factors
Q2 revenue declined 2.7% YoY to $1 billion.
GAAP loss of $0.03/share due to $63.7M charge.
Discovery segment revenue fell 1.9% YoY.
Bullish Signals
Management raised its full-year 2026 non-GAAP EPS guidance to a range of $11.15-$11.45, indicating confidence in future profitability despite near-term revenue challenges.
The Discovery and Safety Assessment segment achieved a net book-to-bill ratio of 1.19 with sequential booking growth of 13%, signaling strong demand that should rebuild backlog.
Non-GAAP EPS of $3.02 exceeded analyst consensus estimates by 11.0%, demonstrating that adjusted operating performance remains robust above market expectations.
The Manufacturing segment expanded its non-GAAP operating margin to 37.8% despite a revenue decline, showcasing improved pricing power or cost efficiency.
Risk Factors
Q2 revenue declined 2.7% year-over-year to $1 billion, indicating ongoing top-line pressure in the current market environment.
GAAP earnings resulted in a loss of $0.03 per share due to a significant $63.7 million charge related to divestitures.
The Discovery and Safety Assessment segment revenue fell 1.9% year-over-year, contributing to the overall top-line weakness.
Charles River Laboratories International reported second-quarter results on August 5, 2026, showing a divergence between top-line revenue and earnings performance. The company generated USD 1 billion in revenue, representing a 2.7 percent year-over-year decline, while adjusted earnings per share (EPS) beat consensus estimates by USD 0.25 to reach USD 3.02 against an expected USD 2.77.
Despite the revenue contraction, the company successfully converted a smaller top line into adjusted earnings that exceeded market expectations. However, the year-over-year EPS decline of USD 0.10 keeps cost control and demand recovery central to the ongoing valuation discussion for this contract research organization.
Following the earnings release, Evercore ISI maintained an Outperform rating on September 11, 2026, lifting its price target from USD 300 to USD 320. As of September 23, 2026, the stock traded at USD 285.94, placing it near the upper end of its yearly range but still 5.7 percent below its 52-week high.
Analysts are focusing on the company's ability to sustain profitability amidst sales declines, with fiscal 2026 adjusted EPS guidance ranging between USD 11.15 and USD 11.45 providing a clear earnings yardstick for investors evaluating the stock's trajectory.
📉 Q2 revenue fell 2.7% year over year to USD 1 billion.
💰 Adjusted EPS beat consensus, reaching USD 3.02.
🏆 Evercore ISI lifted price target to USD 320 with Outperform rating.
📈 Stock traded at USD 285.94 on September 23, 2026.
🎯 Fiscal 2026 adjusted EPS guidance set between USD 11.15 and 11.45.
📉 Charles River Laboratories reported Q2 revenue of USD 1 billion, down 2.7 percent year over year.
💰 Adjusted EPS beat consensus by USD 0.25, reaching USD 3.02 against an estimate of USD 2.77.
🏆 Evercore ISI lifted its price target to USD 320 while maintaining an Outperform rating.
📊 The stock traded at USD 285.94 on September 23, 2026, up 0.29 percent intraday.
🎯 Fiscal 2026 adjusted EPS guidance is set between USD 11.15 and USD 11.45.
📈 The company maintains a market capitalization of approximately USD 13.77 billion.
📉 Year-over-year EPS declined by USD 0.10 despite the earnings beat on adjusted metrics.
Bullish Signals
Adjusted EPS beat by $0.25 to reach $3.02.
Evercore ISI lifted price target from $300 to $320.
Stock traded near yearly high of $285.94.
Risk Factors
Q2 revenue fell 2.7% year over year to USD 1 billion.
Charles River Laboratories (CRL) reported a mixed second quarter characterized by a GAAP loss of $0.03 per share and a revenue decline of 2.7% year-over-year to $1.00 billion. The company posted the loss primarily due to a $63.7 million charge associated with divesting its CDMO and Cell Solutions businesses, as well as certain European Discovery Services sites. Despite these headline numbers, management raised non-GAAP earnings guidance for 2026, citing strong performance in its Digital Services & Analytics (DSA) segment.
The DSA segment achieved its highest net book-to-bill ratio in nearly four years, driven by a collaboration with Medigen Vaccine Biologics Corp to apply next-generation sequencing technology to an enterovirus vaccine program. This partnership leverages Charles River's acquired Pathoquest capabilities and aligns with broader efforts to integrate AI-enabled digital pathology tools to speed up study turnarounds. The Manufacturing segment also showed resilience, with non-GAAP operating margins climbing to 37.8% from the prior year.
Investors are weighing two distinct narratives: a strategic transition involving portfolio cleanup and expansion into new testing corners versus ongoing operational headwinds in Research Models and Services. While organic growth remained sluggish at 0.1%, the company continues its share buyback program, having spent $300 million in the first half of the year with $700 million remaining on authorization. Institutional interest has increased slightly with hedge fund holdings rising to 47, though short interest remains elevated at 6.14%.
📉 GAAP loss of $0.03/share driven by $63.7M divestiture charge.
💰 Revenue fell 2.7% YoY to $1.0B with stagnant organic growth.
🚀 DSA segment raised 2026 guidance after highest net book-to-bill in four years.
🤝 Partnering with Medigen for next-gen sequencing enterovirus vaccine program.
💸 Executed $300M share buybacks with $700M remaining authorized.
📉 Charles River reported a GAAP loss of $0.03 per share in the second quarter, driven by a $63.7 million one-time charge from divesting its CDMO and Cell Solutions businesses.
💰 Revenue fell 2.7% year-over-year to $1.00 billion, with organic growth stagnating at just 0.1%, marking the best performance since 2023.
🚀 The Digital Services & Analytics (DSA) segment posted its highest net book-to-bill in nearly four years, prompting management to raise non-GAAP earnings guidance for 2026.
🤝 Charles River announced a collaboration with Medigen Vaccine Biologics Corp to utilize next-generation sequencing technology for an enterovirus vaccine program.
📈 Manufacturing segment non-GAAP operating margins expanded significantly to 37.8% from 32.8% a year earlier.
💸 The company executed share buybacks, spending $300 million on 1.7 million shares in the first half of the year with $700 million remaining authorized.
📉 Research Models and Services revenue declined 1.8% as demand for small research models weakened in North America.
🏦 Hedge fund ownership increased to 47 from 43, indicating growing institutional interest despite a forward P/E of 22.47.
⚖️ Short sellers maintain a 6.14% short interest, reflecting skepticism about the company's transition costs versus operational progress.
Bullish Signals
Raised 2026 guidance after DSA's highest book-to-bill in four years.
Manufacturing margins expanded to 37.8% from 32.8% year-over-year.
Secured collaboration with Medigen using Pathoquest AI technology.
Spent $300M on buybacks with $700M authorization remaining.
Risk Factors
GAAP loss of $0.03/share from $63.7M divestiture charge.
Revenue declined 2.7% YoY to $1.0B; organic growth 0.1%.
Research Models revenue slid 1.8% on weak North American demand.
Bullish Signals
Charles River raised non-GAAP earnings guidance for 2026 following the DSA segment's highest net book-to-bill in nearly four years.
The Manufacturing segment achieved a significant expansion in non-GAAP operating margins, climbing to 37.8% from 32.8% year-over-year.
Charles River successfully leveraged its acquired Pathoquest technology and AI-enabled digital pathology tools to secure a new collaboration with Medigen Vaccine Biologics Corp.
The company continues an active share repurchase program, having spent $300 million in the first half of the year while maintaining $700 million in remaining authorization.
Risk Factors
Charles River recorded a GAAP loss of $0.03 per share due to a $63.7 million charge from divesting its CDMO and Cell Solutions businesses.
Total revenue declined 2.7% year-over-year to $1.00 billion, with organic growth remaining sluggish at just 0.1%.
The Research Models and Services segment revenue slid 1.8% due to weakening demand for small research models in North America.
Charles River Laboratories International, Inc. (CRL) shares are trading near record levels at $277.71 on the NYSE as of September 21, 2026, driven by a solid earnings outlook and strong investor confidence. The company has issued fiscal year 2026 guidance for earnings per share ranging between $11.15 and $11.45, which aligns closely with analyst consensus estimates of approximately $11.33 EPS.
The narrow spread in the company's guidance range signals high management confidence in delivering stable earnings, framing a tight corridor for potential results that supports current valuation levels. Analyst coverage remains supportive, with Evercore reissuing an outperform rating and setting a price target of $320.00, implying roughly 15.2% upside from recent opening levels.
Institutional ownership stands at approximately 98.91%, though insider selling activity totaling over $42 million in the last ninety days suggests some profit-taking or portfolio rebalancing at strong price levels. The stock currently trades slightly above the average analyst price target of $273.81, implying a forward P/E multiple near 24.6 based on the guidance midpoint.
📈 CRL shares trade at $277.71 with FY 2026 EPS guidance of $11.15-$11.45.
🎯 Analyst consensus estimates FY 2026 EPS at roughly $11.33.
🏦 Institutional ownership is high at 98.91%.
💰 Insiders sold $42.6 million worth of shares over the last ninety days.
🧮 Current valuation implies a forward P/E multiple near 24.6.
📈 CRL shares trade at $277.71, supported by FY 2026 EPS guidance of $11.15 to $11.45 per share.
🎯 Analyst consensus estimates FY 2026 EPS at roughly $11.33, aligning closely with management's outlook.
📊 Evercore reissues an outperform rating with a price target of $320.00, implying ~15.2% upside.
🏦 Institutional ownership is high at 98.91%, indicating strong interest from hedge funds and asset managers.
💰 Insiders sold $42.6 million worth of shares over the last ninety days, reflecting profit-taking behavior.
📉 The stock trades about $3.90 above the average analyst price target of $273.81 reported by MarketBeat.
🧮 Current valuation implies a forward P/E multiple near 24.6 based on the midpoint of FY 2026 guidance.
Charles River Laboratories issued FY 2026 EPS guidance between $11.15 and $11.45, signaling strong management confidence in stable earnings delivery.
Evercore reissued an outperform rating with a price target of $320.00, implying approximately 15.2% upside from the recent opening price of $277.71.
The narrow spread in guidance range indicates high confidence in the company's ability to meet market expectations for fiscal 2026.
Risk Factors
Insiders sold $42.6 million worth of shares over the last ninety days, which may reflect profit-taking or portfolio rebalancing at elevated price levels.
The average analyst price target of $273.81 sits slightly below the current trading price of $277.71, suggesting some analysts have already priced in recent strong performance.
Charles River Laboratories International Inc. (CRL) shares have surged significantly, closing at $281.67 on September 18, 2026, which aligns closely with a fair value estimate of approximately $282. The stock has delivered a robust 90-day gain of 52.25% and a one-year total shareholder return of 79.42%, reflecting strong market enthusiasm for the company's strategic initiatives.
The primary driver behind this recent rally is the successful launch of its rapid cell banking services. This new offering aims to accelerate the preparation and storage of cell lines for biopharmaceutical customers, a capability designed to shorten development timelines and enhance operational efficiency within the life sciences sector.
Analysts suggest that while the rapid cell banking narrative has supported current sentiment, the stock price appears fairly valued relative to recent intrinsic value models. Consequently, investors are advised to monitor whether these operational catalysts can translate into sustained earnings and cash flow growth in upcoming quarters, as much of the immediate upside may already be reflected in the current share price.
📈 CRL stock closed at $281.67, aligning with fair value estimate of $282.
🚀 Company achieved 90-day gain of 52.25% and one-year TSR of 79.42%.
🧬 Launched rapid cell banking services to accelerate biopharmaceutical customer line preparation.
⚡ New offering shortens development timelines, providing key competitive advantage in lab services.
Charles River Laboratories International, Inc. (CRL) shares closed at USD 281.70 on September 17, 2026, posting a 3.0 percent gain as investors reacted positively to the launch of new rapid cell banking programs. These operational initiatives are designed to shorten release timelines for clients, addressing a key priority for biopharma customers seeking accelerated development cycles. The stock also saw significant intraday movement, rising approximately 3.6 percent before settling at the closing level.
Analyst sentiment remains strongly constructive following the operational update, with multiple investment houses lifting their price targets into the USD 300 to USD 330 range. Argus Research raised its fair value estimate by roughly 22 percent to USD 282.43, while TD Cowen and Evercore ISI also increased their targets. Specific analysts like David Toung at Argus maintained a Buy rating with a target of USD 330.00, citing stronger earnings per share growth and improving end markets.
The company continues to benefit from robust demand in the contract research organization space, having gained approximately 41 percent year to date. While valuations are viewed as more growth-oriented than value-focused compared to peers like Progyny, the consensus price target of USD 290.08 suggests moderate upside potential. Future performance will depend on sustaining earnings growth and successfully translating these operational improvements into higher margins.
Key risks identified include valuation sensitivity if growth slows, potential normalization of contract research demand, and competitive pressures within the expanding outsourcing landscape. As the stock trades near its recent 52-week high band, investors are closely watching upcoming earnings releases to determine if the rapid cell banking programs can justify the elevated price targets set by analysts.
📈 Stock closed at $281.70, up 3% after launching rapid cell banking programs.
🚀 Analysts lifted price targets to $300-$330 range citing strong demand.
💰 Argus raised fair value estimate by 22% to $282.43.
📊 Shares gained 41% year-to-date driven by contract research service demand.
⚖️ Trading at forward P/E of 24.87 with 6.3% upside to consensus target.
📈 Charles River Labs stock closed at USD 281.70 on September 17, 2026, up 3.0 percent following the launch of rapid cell banking programs.
🚀 Analysts including Argus, TD Cowen, and Evercore ISI have lifted price targets into the USD 300 to USD 330 range.
💰 Argus Research raised its fair value estimate by approximately 22 percent to USD 282.43 based on revised earnings trajectories.
📊 The company has gained about 41 percent year to date driven by strong demand for contract research services.
🔬 Rapid cell banking programs aim to shorten release timelines, a key consideration for biopharma clients seeking faster development cycles.
🏆 Argus Research analyst David Toung maintained a Buy rating with a specific price target of USD 330.00.
⚖️ Charles River Labs is valued as more growth-oriented than value-focused, trading at a forward P/E ratio of 24.87.
📉 Key risks include valuation sensitivity to growth slowdowns and potential normalization of contract research demand.
🌍 The company benefits from rising R&D costs and growing demand for specialized expertise in the global outsourcing market.
🎯 The consensus analyst price target is USD 290.08, representing about 6.3 percent upside from the current level.
Bullish Signals
Stock gained 3.0% to close at USD 281.70 after launching rapid cell banking programs.
Analysts lift price targets into USD 300-330 range citing stronger earnings growth.
Argus increased fair value estimate by 22% to USD 282.43 reflecting improved revenue trajectory.
Stock delivered strong year-to-date performance of about 41% driven by clinical catalysts.
Analyst maintains Buy rating with price target of USD 330.00 highlighting preclinical demand.
Risk Factors
High valuation risks if growth slows.
Contract research demand may normalize.
Competitive pressures from expanding market.
Bullish Signals
Charles River Labs stock gained 3.0 percent to close at USD 281.70 after launching rapid cell banking programs designed to accelerate release timelines for biopharma clients.
Analyst sentiment is constructive with Argus, TD Cowen, and Evercore ISI lifting price targets into the USD 300 to USD 330 range, citing stronger earnings per share growth.
Argus Research increased its fair value estimate by approximately 22 percent to USD 282.43, reflecting improved model inputs on revenue and earnings trajectories.
The company has delivered a strong year-to-date performance of about 41 percent, driven by clinical catalysts and robust demand for contract research services.
Argus Research analyst David Toung maintained a Buy rating with a price target of USD 330.00, highlighting momentum in preclinical demand.
The stock is positioned to benefit from rising R&D costs and growing demand for specialized expertise in the global contract research outsourcing market.
Risk Factors
Valuation sensitivity poses a risk if growth slows, as the company trades at a premium multiple with less room for disappointment compared to value-oriented peers.
There is a risk of potential normalization of contract research demand after a period of heightened clinical activity in the sector.
The company faces competitive pressures in the broader outsourcing landscape as the market expands and attracts more niche and regional players.
Charles River Laboratories International, Inc. has launched new rapid cell banking programs that integrate Next-Generation Sequencing (NGS) to accelerate release timelines for biopharmaceutical and advanced therapy developers. This comprehensive end-to-end solution is designed to enhance product quality, safety, and regulatory readiness while significantly reducing overall development durations.
The platform achieves a 40% reduction in cell bank production timelines compared to the industry standard of 20 weeks. By combining rapid cell banking packages with advanced NGS characterization, Charles River enables clients to reach critical milestones faster and bring innovative treatments to patients sooner without compromising on safety or compliance.
To support these accelerated timelines, Charles River employs rapid microbiological methods (RMM) for microbial detection using Celsis ATP-Bioluminescence technology and real-time PCR for mycoplasma detection. These automated, objective technologies replace traditional compendial testing, resulting in faster pre-bank and release testing phases that align with global regulatory expectations from the FDA and EMA.
The company further strengthens its capabilities through the integration of Pathoquest, a leader in NGS solutions for in vitro characterization. This acquisition allows Charles River to leverage advanced sequencing-based testing services via its iDTECT platform, ensuring high-quality products are delivered efficiently while maintaining strict CGMP compliance and meeting international regulatory guidance such as ICH Q5A and Q5B.
🚀 Rapid cell banking cuts production timelines by 40% vs industry standard.
🧬 New platform combines rapid cell banks with NGS for full characterization.
🦠 Advanced microbiological methods replace traditional testing to accelerate release.
⚖️ Solutions meet FDA, EMA, and ICH regulatory compliance standards.
🤝 Pathoquest acquisition integrates advanced NGS expertise into quality control.
🚀 Charles River introduces rapid cell banking programs that reduce production timelines by 40% compared to the industry standard of 20 weeks.
🧬 The new platform combines rapid cell bank packages with Next-Generation Sequencing (NGS) for comprehensive end-to-end characterization services.
🦠 Charles River utilizes rapid microbiological methods including Celsis ATP-Bioluminescence technology and real-time PCR to replace traditional testing and accelerate release timelines.
🏛️ The company's solutions are designed to meet stringent global regulatory expectations from the FDA, EMA, and ICH guidelines for accuracy and compliance.
🤝 Charles River acquired Pathoquest to integrate advanced NGS expertise and technology platforms into its existing quality control testing capabilities.
🔬 The iDTECT platform leverages NGS to provide reliable in vitro characterization services that ensure high-quality products are delivered efficiently.
⚖️ These offerings support the company's commitment to the 3Rs by developing alternative methods that reduce reliance on animal testing while supporting efficient product development.
Bullish Signals
Rapid cell banking cuts production timelines by 40% vs industry standard.
New platform combines rapid banking with NGS to accelerate release.
Microbiological methods replace traditional testing for faster timelines.
Pathoquest acquisition strengthens NGS solutions for quality control.
End-to-end solution enhances safety and reduces development timelines.
Bullish Signals
Charles River Laboratories has introduced rapid cell banking programs that achieve a 40% reduction in cell bank production timelines compared to the industry standard of 20 weeks.
The company's new platform combines rapid cell banking with Next-Generation Sequencing (NGS) to significantly accelerate release timelines for biopharmaceutical and advanced therapy developers.
Charles River offers rapid microbiological methods using Celsis ATP-Bioluminescence technology and real-time PCR that replace traditional compendial testing, resulting in faster pre-bank and release testing timelines.
The acquisition of Pathoquest strengthens Charles River's capabilities in NGS solutions for in vitro characterization and quality control testing of biopharmaceutical products.
Charles River delivers a comprehensive, end-to-end solution that enhances product quality, safety, and regulatory readiness while reducing overall development timelines for clients.
Charles River Laboratories International, Inc. (CRL) shares have appreciated over 20% in the past year as management signaled a strategic inflection point at a September 2026 investor conference. The company projects manufacturing margins expanding to approximately 40% and expects annual free cash flow generation of at least USD 500 million during normal years, supporting continued capital deployment for acquisitions and share repurchases.
Key drivers for this recovery include the Drug Safety Assessment (DSA) segment, which posted a book-to-bill ratio of 1.19 in Q2 2026, its highest level in four years. Management anticipates revenue acceleration in DSA during the second half of 2026 following modest growth in the quarter, while the Microbial Solutions segment continues to deliver high single-digit organic growth.
Despite these positive trends, the Research Models and Services (RMS) business is expected to face a low single-digit revenue decline for full-year 2026. Investors are monitoring the stabilization of RMS relative to the stronger performance in DSA and Manufacturing. As of mid-September 2026, the company has deployed roughly USD 800 million in capital year-to-date while maintaining a net debt to EBITDA leverage ratio of about 2.5 times.
Recent stock performance data indicates that while CRL gained about 21.55% over the last year, recent quarterly returns have been relatively flat or slightly negative. The company trades at a market capitalization of approximately USD 13.28 billion with an AI-based price target suggesting limited immediate upside from current levels.
📈 Stock gained over 20% in past year with growth inflection expected H2 2026.
🔬 Drug Safety Assessment book-to-bill hit 1.19 in Q2 2026, highest in four years.
⚠️ Research Models segment projected to see low single-digit revenue decline for full-year 2026.
💸 Company deployed USD 800 million capital including USD 500 million acquisitions and buybacks.
📈 Charles River Laboratories stock has gained over 20% in the past year as management signals a growth inflection starting in the second half of 2026.
💰 The company expects manufacturing margins to approach 40% and generates at least USD 500 million in annual free cash flow in normal years.
🔬 Drug Safety Assessment (DSA) posted a book-to-bill ratio of 1.19 in Q2 2026, the highest level in four years, with revenue expected to accelerate later this year.
📊 Microbial Solutions delivered high single-digit organic growth in Q2 2026 and is expected to remain a solid contributor to overall performance.
⚠️ The Research Models and Services (RMS) segment is projected to experience a low single-digit revenue decline for full-year 2026.
💸 Year-to-date in 2026, the company has deployed about USD 800 million in capital, including USD 500 million for acquisitions and USD 300 million for buybacks.
📉 Recent quarterly performance shows the stock returned about 0.29% over the last quarter and minus 1.46% year-to-date despite annual gains.
🏦 Charles River Laboratories maintains a net debt to EBITDA leverage ratio of approximately 2.5 times as of mid-September 2026.
💵 The stock trades at a market capitalization of about USD 13.28 billion with an AI-based price target of USD 276.92.
Bullish Signals
Margins expanding near 40% by H2 2026.
Drug Safety book-to-bill hit 1.19 in Q2.
Free cash flow guidance raised to $500M.
Microbial Solutions delivered high single-digit organic growth.
Shares gained over 20% on growth signals.
Risk Factors
Stock down 1.46% YTD in 2026.
Quarterly return flat at 0.29%.
Bullish Signals
Charles River Laboratories expects manufacturing margins to expand to near 40% in the second half of 2026, up from the upper 30s range seen in Q2.
The Drug Safety Assessment segment achieved a book-to-bill ratio of 1.19 in Q2 2026, its highest level in four years, indicating strong order intake.
Management raised free cash flow guidance to at least USD 500 million annually in normal years, supporting acquisition spending and share repurchases.
The Microbial Solutions segment delivered high single-digit organic growth in Q2 2026 and is expected to remain a solid contributor.
Shares have gained over 20% over the past year as investors react to management's signals of stabilization and growth inflection.
Risk Factors
Recent stock performance has been flat or slightly negative, with the share returning minus 1.46% year-to-date in 2026.
The company's recent quarterly return was only 0.29%, indicating a lack of immediate momentum despite annual gains.
Charles River Laboratories International, Inc. (CRL) stock closed at USD 283.98 on the New York Stock Exchange on September 8, 2026. The share price is currently trading slightly above the average analyst price target of USD 281, suggesting the market has priced in a portion of expected earnings growth. However, the stock remains below the more optimistic USD 300 target set by TD Cowen, which was lifted in August 2026.
Analyst consensus for the quarter ending September 2026 indicates a mean earnings per share estimate of USD 3.07 based on data from 11 analysts. Estimates have seen a slight upward revision with a mean percentage change of 0.33%, reflecting a tight range between high and low expectations. Long-term growth projections suggest an average annual growth rate of approximately 8.89% in key metrics like earnings.
Valuation ratios for the company show a gradual decline from 22.77 to 18.97 over the forecasted fiscal years, indicating that the market expects earnings expansion to justify current premium multiples. A key risk identified is potential valuation compression if the company fails to meet the upcoming quarterly earnings expectations of USD 3.07 per share, which could lead to a sharper negative reaction from investors than positive surprises.
📈 CRL stock closed at $283.98, trading above analyst targets.
🎯 TD Cowen raised target to $300 for ~5.7% upside.
💰 Analysts project Q3 2026 EPS of $3.07 based on 11 analysts.
📈 Long-term growth expectations indicate an average annual rate of 8.89%.
⚠️ Missing $3.07 EPS could trigger significant valuation compression.
📈 Charles River Labs stock closed at USD 283.98 on September 8, 2026, trading just above the average analyst price target of USD 281.
🎯 TD Cowen raised its price target to USD 300 in August 2026, signaling potential upside of about 5.7% from recent levels.
💰 Analysts estimate mean earnings per share of USD 3.07 for the quarter ending September 2026 based on 11 contributing analysts.
📈 Long-term growth expectations indicate an average annual growth rate of 8.89% in key metrics such as earnings.
📉 Forward valuation ratios are projected to decline from 22.77 to 18.97 over the next several fiscal years as earnings expand.
⚠️ A primary risk is that any disappointment relative to the USD 3.07 EPS estimate could trigger significant valuation compression.
Bullish Signals
Stock trades near USD 281 analyst price target.
TD Cowen lifted target to USD 300 for August 2026.
Q3 2026 earnings estimates revised up by 0.33%.
Long-term growth projected at 8.89% annually.
Risk Factors
Stock trades near analyst targets, limiting upside.
High valuation risks compression if USD 3.07 EPS missed.
Investors may overreact to negative earnings surprises.
Bullish Signals
Charles River Labs stock is trading near the average analyst price target of USD 281, indicating market confidence in current earnings growth expectations.
TD Cowen lifted its price target to USD 300 in August 2026, suggesting a bullish outlook with potential upside from recent closing levels.
Analyst consensus for the quarter ending September 2026 shows a slight upward revision in earnings estimates with a mean percentage change of 0.33%.
Long-term analyst projections support an average annual growth rate of 8.89% in key metrics, justifying a premium multiple if growth continues.
Risk Factors
The stock is trading only a few dollars above the average analyst target, leaving limited near-term upside and discounting much of expected earnings growth.
Valuation ratios stand above 20 on a current-year basis, creating a risk of compression if the company misses the USD 3.07 EPS estimate for the September 2026 quarter.
Investors may react more strongly to negative surprises than positive ones given the current proximity to consensus price targets.
Charles River Laboratories (CRL) reported a stronger-than-expected second quarter, delivering non-GAAP diluted EPS of $3.02 against the $2.73 consensus estimate. This result marked the fifth consecutive quarter where the company exceeded earnings expectations. Revenue reached $1.00 billion, surpassing the $977.20 million consensus by 2.75%, though it declined 2.7% year-over-year primarily due to completed divestitures of the CDMO and Cell Solutions businesses rather than underlying demand issues.
The most significant positive signal emerged from the Drug Safety Assessment (DSA) segment, which achieved its highest net book-to-bill ratio in nearly four years. Management noted broad-based demand improvement across both large biopharmaceutical and small-to-mid-sized biotech clients. Consequently, Charles River raised its full-year guidance, lifting organic revenue growth expectations to 0.0%-1.0% and increasing non-GAAP EPS guidance to $11.15-$11.45, representing a $0.25 midpoint improvement.
Despite the GAAP EPS guidance being trimmed to $3.05-$3.35 to reflect divestiture-related losses recorded in the quarter, operational efficiency improved significantly. Non-GAAP operating margins increased 420 basis points sequentially to 20.5%. The company also highlighted that organic revenue growth of 0.1% was the highest since Q3 2023, driven by higher Microbial Solutions revenue within the Manufacturing segment.
CEO Birgit Girshick stated that the company made excellent progress on its Pathway to Purpose strategy and is actively evaluating opportunities to modernize operations and drive greater efficiency. The company expects deferred compensation plan investment gains to be largely offset by a higher tax rate for the full year, resulting in a negligible net impact to non-GAAP EPS. Overall, the earnings report reflects a strategic pivot toward core regulated testing services with improving demand trends.
Charles River Laboratories delivered non-GAAP diluted EPS of $3.02, beating the consensus estimate by 10.65% and marking the fifth consecutive quarter of exceeding earnings expectations.
Revenue of $1.00 billion topped the consensus by 2.75%, demonstrating resilience despite a year-over-year decline attributed to completed divestitures rather than demand erosion.
The DSA segment reached its highest net book-to-bill ratio in nearly four years, signaling broad-based demand improvement across large biopharmaceutical and small-to-mid-sized biotech clients.
Management raised full-year guidance with organic revenue growth expectations lifted to 0.0%-1.0% and non-GAAP EPS guidance increased to $11.15-$11.45, a $0.25 midpoint improvement.
Non-GAAP operating margin expanded 420 basis points sequentially to 20.5%, indicating strong operational leverage and efficiency gains.
Organic revenue growth of 0.1% was the highest since Q3 2023, driven by a 1.3% increase in Manufacturing segment revenue from higher Microbial Solutions sales.
The company is actively evaluating opportunities to modernize operations and strengthen its leading drug development portfolio centered on regulated testing.
Risk Factors
GAAP EPS guidance was lowered to $3.05-$3.35 due to the net loss on divestitures of the CDMO and Cell Solutions businesses recorded in the quarter.
Deferred compensation plan investment gains are expected to be largely offset by a higher tax rate for the full year, resulting in negligible net impact to non-GAAP EPS.
Arrowstreet Capital Limited Partnership reduced its stake in Charles River Laboratories International (NYSE:CRL) by 11.9% during the first quarter, selling 99,210 shares to hold a remaining position of 737,030 shares valued at approximately $127.1 million. While Arrowstreet decreased its holdings, several other institutional investors increased their positions in the fourth quarter, including Tema Etfs LLC, Los Angeles Capital Management LLC, and Sfam LLC, with Activest Wealth Management showing a significant percentage increase in its small stake.
Analyst sentiment regarding CRL remains mixed but generally positive. CLSA downgraded the stock to a 'hold' rating with a $219 price target, while JPMorgan Chase lowered its target to $160 with a neutral rating. Conversely, Barclays raised its objective to $220 with an 'overweight' rating, and Sanford C. Bernstein set a high target of $250. The consensus rating is currently a 'Moderate Buy' with an average price target of $220.75.
Financially, Charles River Laboratories reported strong quarterly results in May, beating earnings per share estimates of $1.96 with actual EPS of $2.06 and revenue of $995.83 million, which exceeded expectations of $977.46 million. The company provided full-year 2026 guidance ranging between $10.80 and $11.30 per share, slightly below the average analyst expectation of $11.05. Additionally, Director James C. Foster sold a significant portion of his holdings via a pre-arranged trading plan.
📉 Arrowstreet reduced holdings by 11.9% to a $127M stake.
📊 Consensus rating is Moderate Buy with a $220.75 target.
💰 Director Foster sold 75,000 shares for $16.875 million.
📈 Q2 EPS of $2.06 beat estimates; revenue hit $995.83M.
📅 FY 2026 EPS guidance set between $10.80 and $11.30.
📉 Arrowstreet Capital Limited Partnership decreased its holdings in Charles River Laboratories International by 11.9% during the first quarter.
💰 The remaining institutional stake held by Arrowstreet is valued at $127,138,000 as of the latest SEC filing.
📈 Several other institutions including Tema Etfs LLC and Los Angeles Capital Management LLC purchased new stakes in the fourth quarter.
📉 CLSA downgraded CRL from 'outperform' to 'hold' with a price target of $219.00 on July 20th.
📉 JPMorgan Chase dropped its price target from $165.00 to $160.00 and assigned a neutral rating in April.
📈 Barclays raised its price objective to $220.00 and maintained an 'overweight' rating in May.
📈 Sanford C. Bernstein set a high price objective of $250.00 with a Buy rating in July.
📊 The stock currently holds a consensus rating of 'Moderate Buy' with an average analyst price target of $220.75.
💰 Director James C. Foster sold 75,000 shares for $16.875 million under a Rule 10b5-1 trading plan on June 29th.
📈 The company reported EPS of $2.06 in the quarter ended May 7th, beating analyst estimates of $1.96.
💵 Revenue for the quarter reached $995.83 million, surpassing expectations of $977.46 million.
📅 Charles River Laboratories set FY 2026 EPS guidance between $10.80 and $11.30.
Bullish Signals
EPS beat at $2.06 vs $1.96 estimate.
Revenue hit $995.83M vs $977.46M forecast.
Barclays raised target to $220 with 'overweight'.
Bernstein set $250 objective showing bullishness.
Consensus rating is Moderate Buy at $220.75.
Risk Factors
CLSA downgraded stock to 'hold' with $219 price target.
JPMorgan reduced target to $160 with neutral rating.
Director Foster sold 75,000 shares, cutting position by 70%.
Bullish Signals
Charles River Laboratories beat quarterly earnings estimates with reported EPS of $2.06 versus the consensus of $1.96.
The company exceeded revenue expectations, reporting $995.83 million against analyst forecasts of $977.46 million.
Barclays raised its price target to $220 and assigned an 'overweight' rating, indicating strong institutional confidence.
Sanford C. Bernstein set a high price objective of $250, reflecting bullish sentiment from major equity research firms.
The stock maintains a consensus 'Moderate Buy' rating with an average analyst price target of $220.75.
Risk Factors
CLSA downgraded the stock to a 'hold' rating and lowered its price target to $219, signaling caution.
JPMorgan Chase reduced its price target to $160 and assigned a neutral rating, suggesting limited upside potential.
Director James C. Foster executed a significant sale of 75,000 shares, reducing his position by over 70%.
Fifth Third Bancorp increased its stake in Charles River Laboratories International (CRL) by 51.2% during the first quarter, purchasing an additional 6,002 shares to hold a total of 17,733 shares valued at $3,059,000. This move joins a broader trend of institutional accumulation, with major entities like Invesco Ltd., Massachusetts Financial Services Co., Victory Capital Management Inc., Ameriprise Financial Inc., and Norges Bank all establishing or significantly expanding their positions in the medical research company during the fourth quarter.
Analyst sentiment remains mixed but generally positive regarding CRL's long-term prospects. Major banks including Citigroup, Evercore, and Barclays have issued 'buy' or 'outperform' ratings with price targets ranging from $215 to $220 per share. However, JPMorgan Chase recently downgraded its target price to $160 with a 'neutral' rating. The consensus among eleven analysts is currently a 'Moderate Buy' with an average price target of $220.75.
In insider trading news, Director James C. Foster executed a significant sale of 75,000 shares in late June under a pre-arranged Rule 10b5-1 plan, reducing his direct ownership by over 70%. Despite this insider liquidation, institutional investors collectively own 98.91% of the company's outstanding stock. Financial metrics show a market capitalization of $10.59 billion and a negative P/E ratio of -58.49, reflecting recent earnings dynamics.
Charles River Laboratories International operates as a leading provider of research models and preclinical support services for the pharmaceutical and biotechnology sectors. Founded in 1947, the company offers core offerings including discovery, safety assessment, toxicology, and pathology services, alongside the supply of laboratory animals. These capabilities help clients accelerate drug development from early discovery through regulatory submission, serving a critical role in the medical device and life sciences industries.
📈 Fifth Third Bancorp raised CRL position by 51.2% to 17,733 shares.
🏦 Invesco Ltd. increased stake by 115.8% to $537.8 million value.
🚀 Victory Capital surged holdings nearly 10,000% in Q4 quarter.
💰 Ameriprise Financial raised position by 1,491.1% in Q3 period.
📉 Director Foster sold shares for $16.875 million reducing holdings.
📈 Fifth Third Bancorp raised its CRL position by 51.2% in Q1, adding 6,002 shares to a total holding of 17,733 shares valued at $3.059 million.
🏦 Invesco Ltd. increased its stake by 115.8% in Q4, now owning 2.696 million shares worth approximately $537.8 million.
🚀 Victory Capital Management Inc. surged its position by nearly 10,000% in Q4, acquiring 684,586 shares valued at $137.9 million.
🇳🇴 Norges Bank initiated a new stake in CRL during the fourth quarter with a valuation of roughly $96.8 million.
💰 Ameriprise Financial Inc. raised its position by 1,491.1% in Q3, purchasing an additional 575,039 shares worth $96 million.
📉 Director James C. Foster sold 75,000 shares for $16.875 million in June, representing a 70.36% reduction in his personal holdings.
📊 Institutional investors own 98.91% of Charles River Laboratories International's outstanding stock.
🎯 Citigroup and Evercore maintain 'buy' or 'outperform' ratings with price targets around $220 per share.
⚠️ JPMorgan Chase reduced its target price to $160 and issued a 'neutral' rating on the stock.
📈 Barclays raised its price target from $210 to $220 and upgraded the rating to 'overweight'.
🏢 The company has a market capitalization of $10.59 billion with a 52-week trading range between $144.26 and $237.86.
🧬 CRL provides essential preclinical and clinical support services, including toxicology and pathology, for the pharmaceutical industry.
Bullish Signals
Fifth Third Bancorp investment in CRL rose 51.2% in Q1.
Victory Capital increased stake nearly 10,000%.
Norges Bank initiated $96.8 million position.
Analyst price target is $220.75 with 'Moderate Buy' rating.
Quick ratio of 1.03 and current ratio of 1.36.
Risk Factors
Director sold 75k shares, reducing stake by over 70%.
JPMorgan downgraded target to $160 with neutral rating.
Negative P/E ratio of -58.49 indicates earnings challenges.
Bullish Signals
Fifth Third Bancorp significantly increased its investment in CRL by 51.2% in Q1, signaling strong institutional confidence.
Major hedge funds including Invesco Ltd., Victory Capital, and Ameriprise Financial have aggressively accumulated shares, with Victory Capital increasing its stake nearly 10,000%.
Norges Bank, a sovereign wealth fund, initiated a substantial new position valued at approximately $96.8 million.
Analyst consensus is 'Moderate Buy' with an average price target of $220.75, supported by recent upgrades from Barclays and Evercore.
The company maintains a strong balance sheet with a quick ratio of 1.03 and a current ratio of 1.36.
Risk Factors
Director James C. Foster sold 75,000 shares for $16.875 million in June, reducing his personal stake by over 70%.
JPMorgan Chase downgraded its price target to $160 and issued a 'neutral' rating, contrasting with other bullish analysts.
The stock trades at a negative P/E ratio of -58.49, indicating recent earnings challenges or accounting adjustments.
Allspring Global Investments Holdings LLC reduced its stake in Charles River Laboratories International (CRL) by 0.1% during the first quarter, selling 2,280 shares to hold a remaining position of 1,993,316 shares valued at approximately $348.6 million. This holding represents about 0.6% of Allspring's total portfolio and ranks as its 25th largest position. The filing indicates that institutional investors collectively own 98.91% of the company's outstanding stock.
Other institutional activity includes new positions from Tema Etfs LLC, Los Angeles Capital Management LLC, Sfam LLC, Elyxium Wealth LLC, and a significant increase in Activest Wealth Management's holdings, which grew by 10,900.0% to own 220 shares valued at $44,000. Meanwhile, Director James C. Foster executed a pre-arranged Rule 10b5-1 plan sale on June 29th, offloading 75,000 shares for $16.875 million, reducing his personal ownership by over 70% to 31,596 shares.
Analyst sentiment remains mixed with a consensus target price of $220.75 and an average rating of 'Moderate Buy.' Recent reports include Barclays raising its target to $220 with an 'overweight' rating, Citigroup maintaining a 'buy' rating, and Mizuho increasing its target to $230. Conversely, JPMorgan Chase lowered its price objective to $160 with a 'neutral' rating, while BNP Paribas Exane set a $250 price objective. The stock currently trades near its 52-week high of $237.86.
Charles River Laboratories International operates as a leading provider of research models and preclinical support services for the pharmaceutical and biotechnology sectors. Founded in 1947, the company offers core offerings including discovery, safety assessment, toxicology, and pathology services, alongside the supply of laboratory animals and diagnostics to help clients accelerate drug development from early discovery through regulatory submission.
📉 Allspring sold 2,280 shares, retaining 1,993,316 worth $348.6 million.
🏦 Institutional ownership stands at 98.91% with new Q4 stakes added.
💰 Director James C. Foster sold 75,000 shares for $16.875 million.
📊 Market cap is $11.03 billion with a P/E ratio of -60.93.
🎯 Analyst consensus target price is $220.75 with a 'Moderate Buy' rating.
📉 Allspring Global Investments Holdings LLC lowered its CRL stake by 0.1% in Q1, selling 2,280 shares while retaining 1,993,316 shares worth $348.6 million.
🏦 Institutional ownership remains high at 98.91%, with new stakes added by Tema Etfs LLC, Los Angeles Capital Management LLC, Sfam LLC, and Elyxium Wealth LLC in Q4.
📈 Activest Wealth Management significantly increased its position by 10,900.0% to own 220 shares valued at $44,000 after purchasing an additional 218 shares.
💰 Director James C. Foster sold 75,000 shares for $16.875 million under a pre-arranged Rule 10b5-1 trading plan on June 29th.
📊 The stock trades at a market cap of $11.03 billion with a P/E ratio of -60.93 and a beta of 1.40.
🎯 Analyst consensus target price is $220.75 with an average rating of 'Moderate Buy' based on twelve buy, three hold, and one sell ratings.
📈 Barclays raised its price target to $220 with an 'overweight' rating, while Citigroup reiterated a 'buy' rating in recent reports.
📉 JPMorgan Chase lowered its price objective to $160 and assigned a 'neutral' rating in a research note from April 13th.
🎯 BNP Paribas Exane set a $250 price objective for the stock in a report dated July 1st.
📉 Mizuho raised its target price to $230 and maintained a 'neutral' rating following an update on Monday.
🏢 Charles River Laboratories International provides discovery, safety assessment, toxicology, and pathology services for the pharma industry.
🧬 The company supplies laboratory animals and related diagnostics to support drug development from early discovery through regulatory submission.
Bullish Signals
Analyst consensus target price is $220.75.
Barclays upgraded to 'overweight' with $220 target.
Mizuho increased objective to $230.
BNP Paribas Exane set high $250 target.
Activest Wealth expanded holdings by 10,900%.
Risk Factors
JPMorgan lowered price objective to $160 with neutral rating.
Negative P/E ratio of -60.93 indicates current unprofitability.
Director sold 75,000 shares (70% holdings) showing lack of confidence.
Bullish Signals
Analyst consensus target price of $220.75 suggests potential upside if the stock trades below this level, with Citigroup maintaining a 'buy' rating.
Barclays upgraded its stance to 'overweight' and raised the price target to $220, indicating confidence in the company's growth prospects.
Mizuho increased its price objective to $230, reflecting positive sentiment regarding the company's strategic position.
BNP Paribas Exane set a high price objective of $250, signaling strong long-term potential for the stock.
Activest Wealth Management significantly expanded its holdings by 10,900.0%, demonstrating strong institutional interest despite the small absolute share count.
Risk Factors
JPMorgan Chase lowered its price objective to $160 and assigned a 'neutral' rating, indicating caution or lack of immediate upside.
The stock has a negative P/E ratio of -60.93, suggesting the company is currently unprofitable on a trailing basis.
Director James C. Foster sold 75,000 shares representing over 70% of his holdings, which could be interpreted as a lack of confidence in near-term performance.
Institutional investors have made significant adjustments to their positions in Charles River Laboratories International (CRL) during the first quarter of 2026. Boston Trust Walden Corp reduced its stake by 6.4%, selling 19,452 shares and holding a remaining position valued at $49.2 million. Conversely, several other major funds increased their holdings, with Invesco Ltd. growing its position by 115.8% to own over 2.6 million shares valued at $537.8 million, while Victory Capital Management Inc. saw a massive percentage increase in its stake.
Analyst sentiment remains largely positive for the medical research company, with multiple major firms upgrading ratings or raising price targets. Morgan Stanley upgraded CRL to an 'overweight' rating and lifted its price objective to $220. Similarly, CLSA moved to an 'outperform' rating with a $219 target, and Barclays increased its target to $220. The consensus average rating is currently a 'Moderate Buy' with a collective price target of $215.88.
Corporate insider activity includes a notable sale by Director James C. Foster, who sold 75,000 shares for approximately $16.9 million under a pre-arranged trading plan, reducing his personal ownership to roughly 31,596 shares. Despite this insider reduction, hedge funds and institutional investors collectively own 98.91% of the company's outstanding stock. The firm continues to operate as a leading provider of research models and services for the pharmaceutical and biotechnology industries.
📉 Boston Trust Walden Corp sold 19,452 shares in Q1 2026.
📈 Invesco Ltd. holdings jumped 115.8% to $537.8 million.
🚀 Victory Capital Management Inc. stake rose 9,938.8%.
🏦 Institutional investors own 98.91% of total outstanding shares.
🎯 Consensus price target is $215.88 with twelve Buy ratings.
📉 Boston Trust Walden Corp decreased its CRL position by 6.4%, selling 19,452 shares in Q1 2026.
📈 Invesco Ltd. significantly increased its holdings by 115.8% to own 2,696,150 shares valued at $537.8 million.
🚀 Victory Capital Management Inc. boosted its stake by 9,938.8%, acquiring an additional 684,586 shares.
📊 Morgan Stanley upgraded CRL to 'overweight' and raised the price target from $185 to $220.
🔼 CLSA upgraded the stock to 'outperform' with a new price target of $219.00.
💰 Director James C. Foster sold 75,000 shares for $16.875 million under a Rule 10b5-1 plan.
📉 The stock trades at a negative P/E ratio of -61.33 with a market cap of $11.11 billion.
🏦 Institutional investors own 98.91% of the company's total outstanding shares.
🎯 The consensus analyst price target is $215.88 based on twelve Buy ratings and three Hold ratings.
Bullish Signals
Major banks upgraded ratings showing growth confidence.
Invesco Ltd. increased position by over 100%.
Victory Capital and Ameriprise added significant stakes.
Strong balance sheet with quick ratio of 1.03.
Risk Factors
Director sold 75,000 shares, dropping stake by 70.36%.
Stock trades at negative P/E of -61.33.
Bullish Signals
Multiple major investment banks have upgraded their ratings or raised price targets, indicating strong institutional confidence in the company's growth prospects.
Invesco Ltd. has aggressively increased its position by over 100%, signaling a bullish view on the stock's future performance.
Victory Capital Management Inc. and Ameriprise Financial Inc. have also substantially increased their stakes, adding significant institutional buying pressure.
The company maintains a strong balance sheet with a quick ratio of 1.03 and a current ratio of 1.36.
Risk Factors
Director James C. Foster executed a large sale of 75,000 shares, representing a 70.36% decrease in his personal ownership stake.
The stock currently trades at a negative P/E ratio of -61.33, reflecting recent earnings challenges or losses.
CRL has filed a Form 144 with the SEC notifying of a proposed resale of 75,000 shares of its Common Stock via broker UBS Financial Services. The filing lists an aggregate offering price of $16,875,000.00 and reports 48,167,730 shares outstanding as of June 29, 2026. This statutory notice is required when an affiliate plans to sell restricted or control securities to ensure market transparency regarding potential supply increases.
The shares being sold originate from multiple Restricted Stock Unit (RSU) and Performance Stock Unit (PSU) grants issued by the company between 2020 and 2025. Specific grant dates include February 7, 2020; January 31, 2025; November 14, 2023; and May 29, 2024, among others. The filing details the nature of acquisition as RSU/PSU awards from the issuer, documenting the vesting history that led to these securities becoming eligible for resale.
This disclosure indicates an affiliate intends to liquidate a portion of their holdings, potentially impacting short-term share supply and price dynamics depending on execution timing. The broker handling the transaction is UBS Financial Services, Inc., located in New York. The filing includes standard representations regarding material non-public information and adherence to Rule 10b5-1 trading plans if applicable.
Financial analysts and investors should monitor the actual execution of this sale, as the aggregate value of $16.875 million represents a significant transaction relative to typical daily volume for many small-cap stocks. The timing of the sale will depend on market conditions and compliance with resale restrictions, which could influence CRL's stock price in the near term.
📄 CRL filed Form 144 for 75,000 share resale.
💰 Aggregate offering price totals $16,875,000.
🏦 UBS Financial Services handles the transaction.
📅 48,167,730 shares outstanding as of June 29, 2026.
🎁 Shares originate from RSU/PSU grants issued 2020–2025.
📄 CRL filed a Form 144 notifying the SEC of a proposed resale of 75,000 shares of Common Stock.
💰 The aggregate offering price for the proposed sale is listed at $16,875,000.00.
🏦 UBS Financial Services, Inc. is identified as the broker handling the transaction.
📅 As of June 29, 2026, CRL reports 48,167,730 shares outstanding.
🎁 The sold shares originate from various RSU and PSU grants issued between 2020 and 2025.
📊 Specific grant dates include February 7, 2020; January 31, 2025; and November 14, 2023.
⚖️ The filing confirms the affiliate represents no knowledge of material adverse information regarding the issuer.
🕒 Final execution timing depends on market sales and compliance with resale conditions.
📍 The broker's address is listed as Eleven Madison Avenue, New York.
Risk Factors
Sale of 75k shares ($16.875M) increases supply, pressuring price.
Resale signals low confidence or insider liquidity needs.
Risk Factors
💸 A proposed sale of 75,000 shares valued at $16.875 million increases immediate share supply, which could exert downward pressure on the stock price upon execution.
📉 The resale of restricted securities by an affiliate may signal a lack of confidence in near-term valuation or liquidity needs for insiders.
Corient Private Wealth LLC significantly increased its position in Charles River Laboratories International (NYSE:CRL) by 68.5% during the fourth quarter, adding 7,166 shares to a total holding of 17,628 shares valued at $3.5 million. Several other institutional investors also entered new positions or increased stakes, including Tema ETFs LLC, Los Angeles Capital Management LLC, and Sfam LLC, while Activest Wealth Management saw its stake value jump by 10,900% to $44,000.
Analyst sentiment for CRL remains generally positive with a consensus 'Moderate Buy' rating and an average price target of $211.00. Recent upgrades include Barclays raising its target to $220.00 with an 'overweight' rating, CLSA upgrading from 'hold' to 'outperform' with a target of $219.00, and Royal Bank of Canada initiating coverage with an 'outperform' rating at $215.00.
Charles River Laboratories International operates as a leading provider of research models and preclinical support services for the pharmaceutical and biotechnology sectors. Founded in 1947, the company offers discovery, safety assessment, toxicology, and pathology services alongside laboratory animal supply to help clients accelerate drug development from early discovery through regulatory submission.
📈 Corient Private Wealth added 7,166 shares worth $3.5 million in Q4.
📊 Institutional ownership remains high at 98.91% with new ETF stakes.
📈 Activest Wealth increased stake value by 10,900% to $44,000.
📈 Barclays raised price target to $220 and maintains 'overweight' rating.
📈 CLSA upgraded to 'outperform' with a new $219 price target.
📈 Corient Private Wealth LLC increased its CRL holdings by 68.5% in Q4, adding 7,166 shares for a total value of $3.5 million.
📊 Institutional ownership stands at 98.91%, with new stakes acquired by Tema ETFs LLC ($26k), Los Angeles Capital Management LLC ($42k), and Sfam LLC ($43k).
📈 Activest Wealth Management saw its stake value increase by 10,900% to $44,000 after purchasing an additional 218 shares.
📈 Barclays raised its price target from $210.00 to $220.00 and maintained an 'overweight' rating on CRL stock.
📈 CLSA upgraded its rating from 'hold' to 'outperform' and increased the price target from $167.00 to $219.00.
📈 Royal Bank of Canada initiated coverage with an 'outperform' rating and a $215.00 price target.
📊 The stock currently trades with a market cap of $10.39 billion and a PEG ratio of 2.46.
📈 Twelve analysts rate the stock as a Buy, while three hold it and one rates it as a Sell.
🏢 CRL provides essential preclinical and clinical support services to accelerate drug development for pharma and biotech clients.
📉 The stock recently opened at $215.68, trading above its 50-day moving average of $176.98.
Bullish Signals
Corient increased position 68.5% to 17,628 shares worth $3.5 million.
Multiple institutions added stakes totaling over $100k in Q4.
Activest Wealth stake value surged 10,900% to $44,000.
Barclays raised price target to $220 with 'overweight' rating.
CLSA upgraded to 'outperform' with $219 price target.
Bullish Signals
Corient Private Wealth LLC significantly increased its position by 68.5% in Q4, adding 7,166 shares to a total holding of 17,628 shares valued at $3.5 million.
Multiple institutional investors initiated new positions or increased stakes, including Tema ETFs LLC ($26k), Los Angeles Capital Management LLC ($42k), Sfam LLC ($43k), and Elyxium Wealth LLC ($46k).
Activest Wealth Management saw its stake value increase by 10,900% to $44,000 after purchasing an additional 218 shares.
Barclays raised its price target from $210.00 to $220.00 and maintained an 'overweight' rating on CRL stock.
CLSA upgraded its rating from 'hold' to 'outperform' and increased the price target from $167.00 to $219.00.
Royal Bank of Canada initiated coverage with an 'outperform' rating and a $215.00 price target.
The consensus analyst rating is 'Moderate Buy' with an average price target of $211.00 based on reports from twelve analysts.
Twelve research analysts have assigned a Buy rating to the stock, indicating strong institutional confidence in its growth prospects.
Charles River Laboratories International (CRL) is currently under Wall Street scrutiny as analysts remain divided on its valuation and earnings outlook. The company recently reported first-quarter 2026 earnings on May 7, beating consensus estimates with EPS of $2.06 versus the expected $1.96. This beat supports a fundamental view among analysts, though recent trading patterns have shown volatility.
Morgan Stanley has upgraded its stance on Charles River, viewing it as a beneficiary of improved biopharma funding and stronger medium-term demand for contract research services. Conversely, Zacks Investment Research compares CRL closely with Labcorp Holding (LH), arguing that LH currently offers stronger value metrics regarding earnings and price-based ratios, particularly in forward valuation.
As of June 23, 2026, CRL shares trade around $183.79 with a market capitalization of approximately $8.9 billion. The stock has delivered over 23% year-to-date performance but is down about 10.3% year-to-date in the current session context, reflecting a volatile trading pattern in 2026. The company operates globally providing preclinical and clinical research services to pharmaceutical and biotech clients.
📈 Q1 2026 EPS hit $2.06, beating the $1.96 consensus estimate.
🏢 Morgan Stanley upgraded CRL due to strong biopharma funding and demand.
⚖️ Zacks favors Labcorp over CRL based on forward valuation metrics.
💰 Stock trades at $183.79 with an $8.9 billion market cap.
📉 Shares dropped 10.3% year-to-date despite a 23% twelve-month gain.
📈 Charles River Laboratories reported Q1 2026 EPS of $2.06, beating the consensus estimate of $1.96.
🏢 Morgan Stanley upgraded its stance on CRL citing improved biopharma funding and strong medium-term demand.
⚖️ Zacks Investment Research compares CRL to Labcorp Holding (LH), favoring LH on forward valuation metrics.
💰 Stock price is approximately $183.79 with a market cap of roughly $8.9 billion as of June 23, 2026.
📉 Year-to-date performance shows a decline of about 10.3% despite a twelve-month gain of over 23%.
🌍 The company provides preclinical and clinical research services across North America, Europe, and Asia.
🔬 Business scope includes early-stage drug discovery, safety assessment, and laboratory services for regulatory submission.
📊 CRL is a member of the S&P 400 MidCap index within the Healthcare - Life Sciences Tools & Services sector.
Bullish Signals
Q1 2026 EPS of $2.06 beat consensus of $1.96.
Morgan Stanley upgraded stock as biopharma funding beneficiary.
Positioned for stronger medium-term contract research demand.
Shares gained over 23% in twelve months.
Risk Factors
Zacks prefers Labcorp over CRL on earnings and price ratios.
Year-to-date performance is negative at approximately minus 10.3%.
Stock shows volatile trading pattern in 2026 suggesting instability.
Bullish Signals
Q1 2026 earnings per share of $2.06 exceeded the consensus estimate of $1.96, indicating solid operational performance.
Morgan Stanley upgraded its stance on Charles River Laboratories, identifying it as a relative beneficiary of improved biopharma funding.
The company is positioned to benefit from a stronger medium-term demand backdrop for contract research services.
Shares have achieved a twelve-month performance of over 23%, outperforming several smaller peers in the professional services sector.
Risk Factors
Zacks Investment Research argues that Labcorp Holding (LH) offers stronger value metrics on earnings and price-based ratios compared to CRL.
Year-to-date performance has been negative at approximately minus 10.3%, contrasting with the twelve-month gain.
The stock exhibits a volatile trading pattern in 2026, suggesting potential short-term instability despite long-term gains.
Charles River Laboratories International (CRL) is highlighted by Simply Wall St as potentially undervalued following a Morgan Stanley upgrade and a strategic collaboration with Eli Lilly's AI drug discovery platform, TuneLab. The article notes that CRL shares have gained momentum recently, posting a 15.41% return over the past 30 days and a 25.47% total shareholder return over the last year, though longer-term returns remain weaker.
The publication presents two conflicting valuation narratives for the company. A community-driven analysis suggests a fair value of $313.61, implying the stock is undervalued by approximately 41% relative to its recent closing price of $185. This bullish view relies on assumptions of rising margins and accelerating earnings driven by the new AI partnership and an acquisition of K.F. (Cambodia) scheduled for January 2026.
Conversely, Simply Wall St's internal SWS Discounted Cash Flow (DCF) model calculates a future cash flow value of $76.70, suggesting the current market price is actually overvalued. The article concludes by outlining key risks to the bullish thesis, including potential setbacks to the Cambodia acquisition and tighter regulations on primate research that could constrain the company's capacity.
📈 Morgan Stanley upgrades CRL amid Eli Lilly AI collaboration.
📊 Stock gained 15.41% in 30 days with 25.47% annual return.
💰 Community analysis suggests 41% undervaluation at current $185 price.
⚠️ Simply Wall St DCF model values stock at only $76.70.
🐒 Risks include Cambodia acquisition delays and primate research regulations.
📈 Charles River Laboratories International (CRL) recently received a Morgan Stanley upgrade and announced a collaboration with Eli Lilly's AI drug discovery platform, TuneLab.
📊 The stock has shown recent momentum with a 15.41% return over the past 30 days and a 25.47% one-year total shareholder return.
💰 A community analysis pegs CRL's fair value at $313.61, suggesting the current price of $185 represents a 41% undervaluation opportunity.
🤝 The company is pursuing an acquisition of K.F. (Cambodia) in January 2026 to expand its research ecosystem.
⚠️ Simply Wall St's internal DCF model contradicts the bullish view, valuing the stock at $76.70 based on future cash flow projections.
🐒 Key risks include potential delays or failures in the Cambodia acquisition and stricter regulations affecting primate research capacity.
Bullish Signals
Morgan Stanley upgrade signals strong institutional confidence.
AI collaboration with Eli Lilly boosts drug discovery.
Stock gained 15.41% this month and 25.47% yearly.
Trading below fair value suggests a buying opportunity.
Risk Factors
DCF model implies $185 price is overvalued vs $76.70 fair value.
Stricter primate research regulations may constrain core revenue streams.
Bullish Signals
Morgan Stanley has upgraded Charles River Laboratories International, signaling increased institutional confidence in the company's prospects.
A new collaboration with Eli Lilly's AI platform, TuneLab, is expected to enhance drug discovery capabilities and potentially drive future revenue growth.
The stock has delivered strong short-term performance with a 15.41% gain over the last month and a 25.47% total return over the past year.
Analyst consensus fair value estimates suggest the stock is trading significantly below its perceived worth, creating a potential buying opportunity.
Risk Factors
Simply Wall St's internal Discounted Cash Flow (DCF) model values the company at $76.70, implying the current market price of $185 may be overvalued.
Tighter regulatory environments regarding primate research could constrain Charles River Laboratories International's core research capacity and revenue streams.
Your Privacy
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Measure audience engagement and site statistics to understand how our services are used (Google Analytics)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
You can accept all cookies or configure your preferences. You can change them at any time via the "Manage Cookies" link in the footer.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Analytics cookies
Help us understand how visitors interact with our website using Google Analytics. These cookies collect information anonymously.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
